Published 6 issues per year
ISSN Print: 1040-8401
ISSN Online: 2162-6472
Indexed in
Complement in Antibody-Based Tumor Therapy
ABSTRACT
Monoclonal antibodies constitute a major treatment option for many tumor patients. Due to their specific recognition sites in their constant Fc regions, antibodies are able to trigger antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). While the contribution of ADCC to clinical efficacy has been strengthened by observations that patients with favorable Fcγ receptor polymorphisms display better response rates to therapeutic antibodies, the contribution of CDC to their clinical efficacy remains controversial. In the background of high expression of complement-regulatory proteins on tumor cells as well as of the fact that some therapeutic antibodies lack the capacity to trigger efficient CDC, strategies have been implemented to improve either the capacity of antibodies to initiate the complement cascade or to interfere with tumor cells' resistance mechanisms. Although both strategies have demonstrated therapeutic benefit in vitro and in murine models, CDC-enhanced antibodies−to the best of our knowledge−have not been clinically tested, and evidence for the potential of CDC-optimizing approaches has yet to be generated in humans. Hence, the potency of complement activation and its impact on the clinical efficacy of therapeutic antibodies still remains to be elucidated in clinical trials encompassing novel complement-enhancing molecules.
-
Melis Joost P.M., Strumane Kristin, Ruuls Sigrid R., Beurskens Frank J., Schuurman Janine, Parren Paul W.H.I., Complement in therapy and disease, Molecular Immunology, 67, 2, 2015. Crossref
-
Taylor Ronald P., Lindorfer Margaret A., Cytotoxic mechanisms of immunotherapy: Harnessing complement in the action of anti-tumor monoclonal antibodies, Seminars in Immunology, 28, 3, 2016. Crossref
-
Ramos Theresa N., Arynchyna Anastasia A., Blackburn Tessa E., Barnum Scott R., Johnston James M., Soluble membrane attack complex is diagnostic for intraventricular shunt infection in children, JCI Insight, 1, 10, 2016. Crossref
-
Derer Stefanie, Cossham Michael, Rösner Thies, Kellner Christian, Beurskens Frank J., Schwanbeck Ralf, Lohse Stefan, Sina Christian, Peipp Matthias, Valerius Thomas, A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells, The Journal of Immunology, 195, 10, 2015. Crossref
-
Stasiłojć Grzegorz, Österborg Anders, Blom Anna M., Okrój Marcin, New perspectives on complement mediated immunotherapy, Cancer Treatment Reviews, 45, 2016. Crossref
-
Reis Edimara S., Mastellos Dimitrios C., Ricklin Daniel, Mantovani Alberto, Lambris John D., Complement in cancer: untangling an intricate relationship, Nature Reviews Immunology, 18, 1, 2018. Crossref
-
Sina Christian, Kemper Claudia, Derer Stefanie, The intestinal complement system in inflammatory bowel disease: Shaping intestinal barrier function, Seminars in Immunology, 37, 2018. Crossref
-
Olcina Monica M, Kim Ryan K, Melemenidis Stavros, Graves Edward E, Giaccia Amato J, The tumour microenvironment links complement system dysregulation and hypoxic signalling, The British Journal of Radiology, 2018. Crossref
-
Macor Paolo, Capolla Sara, Tedesco Francesco, Complement as a Biological Tool to Control Tumor Growth, Frontiers in Immunology, 9, 2018. Crossref
-
Gialeli Chrysostomi, Gungor Bilgi, Blom Anna M., Novel potential inhibitors of complement system and their roles in complement regulation and beyond, Molecular Immunology, 102, 2018. Crossref
-
Olcina Monica M., Balanis Nikolas G., Kim Ryan K., Aksoy B. Arman, Kodysh Julia, Thompson Michael J., Hammerbacher Jeff, Graeber Thomas G., Giaccia Amato J., Mutations in an Innate Immunity Pathway Are Associated with Poor Overall Survival Outcomes and Hypoxic Signaling in Cancer, Cell Reports, 25, 13, 2018. Crossref
-
Li Lei, Yang Hong, Li Yan, Li Xiao-Dong, Zeng Ting-Ting, Lin Su-Xia, Zhu Ying-Hui, Guan Xin-Yuan, Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression, Cell Death Discovery, 4, 1, 2018. Crossref
-
Li Xiang, Lan Xu, Wang Grace, Liu Yi, Zhao Ke, Lu Shan-Zheng, Xu Xiao-Xi, Shi Gang-Gang, Ye Kui, Zhang Bao-Ren, Zhao Yi-Ming, Han Hong-Qiu, Du Cai-Gan, Ichim Thomas E., Wang Hao, Skin Allografting Activates Anti-tumor Immunity and Suppresses Growth of Colon Cancer in Mice, Translational Oncology, 11, 4, 2018. Crossref
-
Bordron Anne, Bagacean Cristina, Tempescul Adrian, Berthou Christian, Bettacchioli Eléonore, Hillion Sophie, Renaudineau Yves, Complement System: a Neglected Pathway in Immunotherapy, Clinical Reviews in Allergy & Immunology, 58, 2, 2020. Crossref
-
Fischinger Stephanie, Fallon Jonathan K., Michell Ashlin R., Broge Thomas, Suscovich Todd J., Streeck Hendrik, Alter Galit, A high-throughput, bead-based, antigen-specific assay to assess the ability of antibodies to induce complement activation, Journal of Immunological Methods, 473, 2019. Crossref
-
Preisker Sophie, Brethack Ann-Kathrin, Bokemeyer Arne, Bettenworth Dominik, Sina Christian, Derer Stefanie, Crohn’s Disease Patients in Remission Display an Enhanced Intestinal IgM+ B Cell Count in Concert with a Strong Activation of the Intestinal Complement System, Cells, 8, 1, 2019. Crossref
-
Seguin‐Devaux Carole, Plesseria Jean‐Marc, Verschueren Charlène, Masquelier Cécile, Iserentant Gilles, Fullana Marie, Józsi Mihály, Cohen Jacques H. M., Dervillez Xavier, FHR4‐based immunoconjugates direct complement‐dependent cytotoxicity and phagocytosis towards HER2‐positive cancer cells, Molecular Oncology, 13, 12, 2019. Crossref
-
Liu Alvin Y., Kanan Adelle D., Radon Tomasz P., Shah Siama, Weeks Mark E., Foster Julie M., Sosabowski Jane K., Dumartin Laurent, Crnogorac-Jurcevic Tatjana, AGR2, a unique tumor-associated antigen, is a promising candidate for antibody targeting, Oncotarget, 10, 42, 2019. Crossref
-
Levin Steven D., Evans Lawrence S., Bort Susan, Rickel Erika, Lewis Katherine E., Wu Rebecca P., Hoover Joseph, MacNeil Sean, La David, Wolfson Martin F., Rixon Mark W., Dillon Stacey R., Kornacker Michael G., Swanson Ryan, Peng Stanford L., Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains, Frontiers in Immunology, 10, 2020. Crossref
-
Elvington Michelle, Liszewski M. Kathryn, Atkinson John P., CD46 and Oncologic Interactions: Friendly Fire against Cancer, Antibodies, 9, 4, 2020. Crossref
-
Taylor Ronald P., Lindorfer Margaret A., How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca2+, Antibodies, 9, 3, 2020. Crossref
-
Liu Rena, Oldham Robert, Teal Emma, Beers Stephen, Cragg Mark, Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment, Antibodies, 9, 4, 2020. Crossref
-
O’Brien Rebecca M., Cannon Aoife, Reynolds John V., Lysaght Joanne, Lynam-Lennon Niamh, Complement in Tumourigenesis and the Response to Cancer Therapy, Cancers, 13, 6, 2021. Crossref
-
Wang Bo, Gallolu Kankanamalage Sachith, Dong Jianbo, Liu Yue, Optimization of therapeutic antibodies, Antibody Therapeutics, 4, 1, 2021. Crossref
-
Shalapour Shabnam, Karin Michael, The neglected brothers come of age: B cells and cancer, Seminars in Immunology, 52, 2021. Crossref
-
Y. Liu Alvin, Crnogorac-Jurcevic Tatjana, J. Lai James, Lam Hung-Ming, Antibody Therapy Targeting Cancer-Specific Cell Surface Antigen AGR2, in Advances in Precision Medicine Oncology, 2021. Crossref
-
Murer Patrizia, Kiefer Jonathan D., Plüss Louis, Matasci Mattia, Blümich Sandra L., Stringhini Marco, Neri Dario, Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin, Journal of Investigative Dermatology, 139, 6, 2019. Crossref
-
Skarzynski Martin, Niemann Carsten U., Lee Yuh Shan, Martyr Sabrina, Maric Irina, Salem Dalia, Stetler-Stevenson Maryalice, Marti Gerald E., Calvo Katherine R., Yuan Constance, Valdez Janet, Soto Susan, Farooqui Mohammed Z.H., Herman Sarah E.M., Wiestner Adrian, Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy, Clinical Cancer Research, 22, 1, 2016. Crossref
-
Gehlert Carina Lynn, Rahmati Pegah, Boje Ammelie Svea, Winterberg Dorothee, Krohn Steffen, Theocharis Thomas, Cappuzzello Elisa, Lux Anja, Nimmerjahn Falk, Ludwig Ralf J., Lustig Marta, Rösner Thies, Valerius Thomas, Schewe Denis Martin, Kellner Christian, Klausz Katja, Peipp Matthias, Dual Fc optimization to increase the cytotoxic activity of a CD19-targeting antibody, Frontiers in Immunology, 13, 2022. Crossref